Identifiying and properly using biomarkers can greatly benefit treating the right patient at the right time with the right drug. We are moving from the ‘one biomarker: one drug’ scenario towards a more integrated approach with multiple biomarkers and drugs. At Oncode we are very active in this new paradigm and we aim to pave the way for the introduction of novel strategies in the field of targeted cancer drug development.